

24th International Conference on Screening for Lung Cancer

The Biodesign Institute, Tempe, AZ
February 25-26, 2011

The broadest mission of these Conferences is collective pursuit of understanding of the issues surrounding early diagnosis and early treatment of lung cancer. Given the announcement by the National Cancer Institute on the National Lung Screening Trial (NLST) that CT screening for lung cancer significantly reduces mortality in high-risk participants, the focus of this meeting is continued updating of an optimal regimen of screening to reduce the potential harms and cost of screening and the continued development of clinical trials to assess treatment alternatives for early lung cancer. The International Lung Cancer Consortium (ILCCO) and International Early Lung Cancer Action Program (I-ELCAP) are holding joint sessions on Friday and Saturday morning.

Friday Morning, February 25, 2011

McCormick Ranch, 7401 North Scottsdale Road, Scottsdale, AZ

- 9:00 – 9:20** **Welcome.** Moderator: P. Boffetta, J.P. Smith
The Biodesign Institute, Arizona State University – A. Nelson
- 9:20 – 9:40** **Overview of ILCCO and I-ELCAP**
ILCCO – R. Hung
I-ELCAP – C. Henschke
- 9:40 – 10:15** **Keynote Lecture**
Early detection research and personalized medicine – J. LaBaer
- 10:15 – 10:45** **Coffee Break and Group Photo**
- 10:45 – 11:00** **NLST Update.** Moderator: C. Henschke
Preliminary NLST results – C. Zylak
- 11:00 – 1:00** **I-ELCAP Update.** Moderator: J. Zulueta
Potential harms of screening – C. Henschke
Unnecessary workup – C. Henschke
Radiation exposure in a given round of screening – D. Gur
Unnecessary surgery – R. Flores
- Discussion
- 1:00 – 2:00** **Lunch**



24th International Conference on Screening for Lung Cancer

The Biodesign Institute, Tempe, AZ
February 25-26, 2011

Friday Afternoon, February 25, 2011
McCormick Ranch, 7401 North Scottsdale Road, Scottsdale, AZ

2:00 – 3:30 **Possible Treatment Trials for Early Lung Cancer.** Moderator: D. Vafai
Future direction of lung cancer treatment – H. Kato
Neoadjuvent trials – R. McKenna
Critical questions to be addressed in drug development – A. Voss
The role of biomarkers – S. Hanash
The Quantitative Imaging Biomarker Response Assessment (QIBA)
– A. Buckler

Discussion

3:30 – 4:00 **Coffee Break**

4:00 – 5:00 **Selected Presentations.** Moderator: S. Aguayo
Accurate pathologic diagnosis of lung cancer – M.D. Lozano

Pan-Canadian Early Lung Cancer Detection Study – H. Roberts
Long-term trends in a surgical cohort: smoking, cell-type – R. McKenna
Cell-CT and autofluorescent biomarkers – R. Johnson
Cell-CT for early lung cancer detection – M. Meyer
Absence of coronary artery calcification as a marker of favorable prognosis
in high risk patients – J. Shemesh

5:00 – 5:30 **Poster Presentations.** Moderator: D. Ray

6:30 **Cocktails and Dinner**
Entertainment



24th International Conference on Screening for Lung Cancer

The Biodesign Institute, Tempe, AZ
February 25-26, 2011

Saturday Morning, February 26, 2011
McCormick Ranch, 7401 North Scottsdale Road, Scottsdale, AZ

- 9:00 – 11:00** **Joint Session – ILCCO and I-ELCAP**
Moderators: R. Hung, D. Yankelevitz
Biosignatures and the Lung Cancer Demonstration Project – D. Meldrum
Four topics of interest to both groups of researchers
- 9:00 – 11:30** **Coordinators Meeting**
- 11:00 – 11:30** **Coffee Break**
- 11:30 – 12:30** **Steering Committee Meeting**
- 1:00 – 2:00** **Lunch**
- 2:00 – 3:15** **Assessing the Benefit of Screening.** Moderator: D. Yankelevitz
Measuring mortality reduction in randomized screening trials: implications for analysis of the NLST – J. Hanley
Curability gain vs. mortality reduction as measures of benefit of screening – O. Miettinen
- Discussion
- 3:15 – 5:00** **Outlooks on Screening for Lung Cancer.** Moderator: J. Mulshine
Economic viewpoint – B. Pyenson
Integrating lung cancer screening with smoking cessation: An idea whose time has arrived – C. Heaton
Further efficiencies by bundling of screenings – J. Mulshine
Viewpoint of high-value, cost-conscious health care in today's health care system – M. Starkey
Consumer viewpoint – L. Fenton
- Discussion

